Northwest Biotherapeutics, Inc.
NWBO
$0.25
$0.00-0.83%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 105.17% | -74.46% | 20.50% | 31.46% | -45.67% |
| Total Depreciation and Amortization | 53.74% | 0.77% | 3.82% | -0.60% | -4.02% |
| Total Amortization of Deferred Charges | 48.31% | -21.14% | 57.19% | -61.07% | 55.72% |
| Total Other Non-Cash Items | -277.81% | 236.80% | 2.36% | -40.96% | -26.66% |
| Change in Net Operating Assets | -135.35% | -45.64% | -23.65% | 205.56% | -45.10% |
| Cash from Operations | -6.27% | -107.73% | 28.99% | 53.33% | -145.12% |
| Capital Expenditure | -348.02% | 33.55% | -226.88% | -19.23% | 55.68% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Investing | -76.41% | -68.75% | -226.88% | -19.23% | 55.68% |
| Total Debt Issued | 61.30% | 35.20% | -26.29% | -40.50% | 141.28% |
| Total Debt Repaid | 100.00% | -160.33% | 69.69% | -58.90% | 52.37% |
| Issuance of Common Stock | -58.56% | -33.62% | 42.51% | 21.69% | -40.84% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 17.56% | -7.15% | 6.09% | -26.40% | 37.19% |
| Foreign Exchange rate Adjustments | -81.86% | 178.90% | -142.21% | -145.54% | 212.69% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -722.95% | -84.12% | 154.47% | 179.06% | -1,417.24% |